Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine

Abstract

Inhibition of the EGFR signaling pathway is one of the attractive therapeutic targets for pancreatic cancer as recent studies demonstrated that EGFR is over‐expressed in pancreatic cancer. In this article we have demonstrated the design of targeted drug delivery system containing Bovine Serum Albumin (BSA) microspheres as delivery vehicle, gemcitabine as anticancer drug and anti‐EGFR (epidermal growth factor receptor) monoclonal antibody as targeting agent. The conjugated BSA microspheres were characterized by several physico‐chemical techniques such as scanning electron microscope, optical microscopy, fluorescent microscopy etc. Administration of these BSA microspheres containing gemcitabine and anti‐EGFR (BSA‐Gem‐EGFR) shows significant inhibition of pancreatic cancer cells (AsPC1) compared to the cells treated with only BSA microspheres, BSA with gemcitabine (BSA‐Gem), and free gemcitabine. This strategy could be used as a generalized approach for the treatment of pancreatic cancer along with other cancers which overexpress EGFR on cell surface. Copyright © 2012 John Wiley & Sons, Ltd.

Bioimaging Tools Based on Polyelectrolyte Microcapsules Encoded with Fluorescent Semiconductor Nanoparticles: Design and Characterization of the Fluorescent Properties

“…The use of proteins, such as BSA, for surface modification makes the polymer microcapsules more biocompatible and more resistant to adhesion with one another. This also ensures temporary passivation of the microcapsule surface, which is important for the subsequent study of the microcapsules formed by PAH–PSS or PAH–PAA interpolymer complexes in terms of in vitro interaction with cells and in vivo behavior [27–29].…”

Designing Natural Polymer-Based Capsules and Spheres for Biomedical Applications—A Review

“…A solid core of various natural [11] as well as synthetic polymers [24], metallic particles [23], and compo- Polymeric capsule shells, with a variety of compositions, have been prepared. These shell compositions may involve (a) a single type of natural polymer, such as chitosan [15] or albumin [16]; (b) composites of different types of natural polymers, such as BSAalginate [17]; (c) composites of different types of natural and synthetic polymers, such as collagen-PLGA [18]; (d) natural polymers functionalized by other materials, including inorganic nanoparticles [19], functionalizing polymers [10], antibodies [20], and a variety of other materials. Diverse core materials have been encapsulated, in solid [21] or liquid form [22,23], within these shells, either as carriers of different types of active pharmaceutical cargo (APC) or made directly of the solid or liquid APCs (see Figure 2).…”

“…A higher concentration of the drug at the desired site can be ensured through targeted delivery by preventing undesired drug loss and adverse effects at the untargeted sites. For targeted delivery of APC, the capsule shell is usually functionalized with various ligands, such as peptides [34], polymers [35], antibodies [20], nucleic acids, and vitamins [22]. Physically stimulated targeted delivery formulations have also been developed, wherein superparamagnetic particles have been functionalized on the microcapsule shell for the magnetically stimulated delivery of capsules at the target site [19].…”

Sonochemistry‐Assembled Stimuli‐Responsive Polymer Microcapsules for Drug Delivery

“…Antibodies are perhaps the primary class of receptor targeting agents, so it is an attractive strategy to develop antibody‐conjugated PMs for drug targeted delivery. Based on the previous study, Grinberg et al have designed a targeted drug system (BSA‐Gem‐EGFR conjugates) with BSA microspheres as delivery vehicle, gemcitabine (Gem) as anticancer drug and anti‐EGFR (epidermal growth factor receptor) monoclonal antibody as targeting agent . They tested the inhibitory effect of cell proliferative activity of BSA microspheres, BSA microspheres with gemcitabine (BSA‐Gem) and BSA‐Gem‐EGFR conjugates, along with controlled pristine gemcitabine against pancreatic cells (AsPC‐1), and the results showed that BSA‐Gem‐EGFR conjugates had a significant inhibition of proliferation of AsPC‐1 cells (31%) compared to BSA microspheres alone (0%), controlled pristine gemcitabine (15%) and BSA‐Gem (25%).…”